top of page

PRE-PROGRAM*

DAY 1 : February 24

14:55

Predict to prevent brain diseases’ progression : application to clinical trial design and patient identification

​

Stanley Durrleman, INRIA Researcher at ICM, INRIA

14:30

Synthetic data: utility, privacy and evaluation

​

Stéphanie Allassonnière, Professor, Université Paris Cité médecine

14:05

Digital twin applications for increasing trial efficiency

​

​

Devanarayan Viswanath, Head Clinical Data Science, Eisai, Inc

12:30

Break

12:05

Impact on regulatory decision making and the lifecycle of uncertainty

​

Cécile Ollivier, Senior Vice President Global Affairs, Critical Path Institute)

11:40

From trial data to HTA dossier: what LLM automation changes in practice

​

​​Bill Malcolm, Executive Director - EAI GHEOR, Bristol Myers Squibb

11:15

Current practice: the US perspective and the global trends

​

​Tina Morrison, Global Harmonization Task Force Leader, Avicenna Alliance

10:45

Break

10:20

Case Study in MHRA sandbox: Using Synthetic Data to Enable Robust Subgroup Analysis in a Pivotal RRMM Trial

​​​

​Federico Mattiello, Biostatistician, Roche

09:55

Virtual patients in drug development and regulatory decision making

​

Piet van der Graaf, Senior Vice President QSP & Professor of Systems Pharmacology and Pediatrics, Certara

09:30

Model-informed development: what qualifies as fit-for-purpose

​

Flora Musuamba, Professor, Université de Namur

09:00

Regulatory opening: where the agency stands

MORNING

AI-enabled evidence in regulatory and HTA practice today

AFTERNOON

Methods in the making

15:20

Break

15:45

Tabular foundation models: one pass, no training. What changes for clinical evidence?

​

Marine Le Morvan, Research Scientist, INRIA

16:10

Three submitted communications

16:40

Reusable models versus ad-hoc analyses

​

Billy ​Amzal, Program intelligence, modeling and AI for Global Health, Gates Foundation

DAY 2 : February 25

11:00

How biostatistics evolves through systematic AI use

​

Marc Buyse, Founder of IDDI

10:35

Three submitted communications

10:05

Break

09:40

RWE agencies will trust

​

Olaf Klungel, Professor Pharmacoepidemiologic Methods, Utrecht University

09:15

What regulators could do with trial data, and why they have not

08:50

DARWIN EU: building the foundations for AI-enabled evidence generation

11:30

Data access as the binding constraint

Wim Goettsch, Coördinator, SUSTAIN-HTA

12:00

Break

13:30

When AI writes the report: the inspection burden

13:55

AI use in biostatistics - safely collaborating with agents in a high-stakes, regulated setting

​

Peter Krusche, Global Head, AI & Data Engineering, Novartis

14:20

Mechanistic Modeling hybridized with Agentic AI

​

Frédéric Cogny, Co-Chief Executive Officer Nova In Silico

14:45

Break

15:00

The unmet needs: what no method answers yet

MORNING

Data & biostatistics as the foundation

AFTERNOON

The generative turn and the regulatory response

16:15

Closing remarks and outlook to 2028

* currently under development and subject to change.

bottom of page